Editas Medicine, Inc. reported the first quarter 2026 results: net income net loss attributable to common stockholders was $25.0 million , or $0.26 per share.
“expenditure requirements into the third quarter of 2027. First Quarter 2026 • For the three months ended March 31, 2026 , net loss attributable to common stockholders was $25.0 million , or $0.26 per share, compared to net loss of $76.1 million , or $0.92 per share, for the same period in 2025 . • Collaboration and other research and development revenues”
Auditor Changes
Editas Medicine, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“appointed PricewaterhouseCoopers LLP (“PwC”) to serve as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2026”
Auditor Changes
Editas Medicine, Inc. dismissed Ernst & Young LLP as its auditor.
“dismissed Ernst & Young LLP (“Ernst & Young”) as the Company’s independent registered public accounting firm, effective immediately”
Governance Changes
Editas Medicine, Inc.: Increased authorized shares of capital stock from 200,000,000 to 395,000,000 and common stock from 195,000,000 to 390,000,000 (effective 2025-06-02).
“At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s capital stock from 200,000,000 to 395,000,000 and the number of authorized shares of the Company’s common stock from 195,000,000 to 390,000,000. The additional common stock authorized by the Certificate of Amendment has rights identical to the Company’s currently outstanding common stock. The Company filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 2, 2025.”
Amy Parison was appointed as Senior Vice President, Chief Financial Officer and Treasurer at Editas Medicine, Inc..
“In connection with Mr. Lucera’s resignation, on March 19, 2025 the Company appointed Amy Parison, Senior Vice President, Finance as Senior Vice President, Chief Financial Officer and Treasurer of the Company, to be effective as of the close of business on March 28, 2025.”
Erick Lucera departed as Executive Vice President, Chief Financial Officer at Editas Medicine, Inc..
“On March 18, 2025, Erick Lucera, Executive Vice President, Chief Financial Officer of Editas Medicine, Inc. (the “Company”) informed the Company that he will be resigning from his position effective March 28, 2025.”
Akshay Vaishnaw resigned as Director at Editas Medicine, Inc..
“On June 27, 2024, Akshay Vaishnaw informed the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”) of his resignation from the Board effective as of June 30, 2024.”
Earnings Releases
Editas Medicine, Inc. reported first quarter 2024 results: net income net loss of $62.0 million, EPS -$0.76.
“For the three months ended March 31, 2024, net loss attributable to common stockholders was $62.0 million, or $0.76 per share, compared to net loss of $49.0 million, or $0.71 per share, for the same period in 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.